Abstract
The relationship between genotype and phenotype in mitochondrial diseases is complicated and poorly understood. The clinical manifestations of mitochondrial diseases vary dramatically in terms of symptoms, severity and age of onset. Furthermore, the same genetic defect can result in different symptoms amongst various individuals whereas different mutations can lead to the same phenotype. Such variation makes it impossible to predict the phenotypes of mitochondrial disease based on genetic defects. Since mitochondria are crucial for energy supply, it has traditionally been accepted that ATP depletion is the main contributing factor to the symptoms associated with mitochondrial diseases. However, as mitochondria participate in such a diverse range of cellular functions and since the phenotypes of mitochondrial disease are extremely variable, the pathology of human mitochondrial diseases may be due to alterations in any of the various mitochondrial functions. For example, the tissue dysfunction associated with specific mitochondrial diseases may be due to excessive ROS production, altered calcium homeostasis which stimulates apoptosis or, as recent work has shown, activation of stress-sensitive signalling pathways. This review highlights these various mechanisms implicated in the cytopathology of mitochondrial disease and dysfunction.
Keywords: Mitochondrial disease, pathogenic mechanisms, ROS, ageing, calcium signalling, AMPK
Current Chemical Biology
Title: Cytopathological Mechanisms in Mitochondrial Disease
Volume: 4 Issue: 1
Author(s): Lisa Francione and Paul R. Fisher
Affiliation:
Keywords: Mitochondrial disease, pathogenic mechanisms, ROS, ageing, calcium signalling, AMPK
Abstract: The relationship between genotype and phenotype in mitochondrial diseases is complicated and poorly understood. The clinical manifestations of mitochondrial diseases vary dramatically in terms of symptoms, severity and age of onset. Furthermore, the same genetic defect can result in different symptoms amongst various individuals whereas different mutations can lead to the same phenotype. Such variation makes it impossible to predict the phenotypes of mitochondrial disease based on genetic defects. Since mitochondria are crucial for energy supply, it has traditionally been accepted that ATP depletion is the main contributing factor to the symptoms associated with mitochondrial diseases. However, as mitochondria participate in such a diverse range of cellular functions and since the phenotypes of mitochondrial disease are extremely variable, the pathology of human mitochondrial diseases may be due to alterations in any of the various mitochondrial functions. For example, the tissue dysfunction associated with specific mitochondrial diseases may be due to excessive ROS production, altered calcium homeostasis which stimulates apoptosis or, as recent work has shown, activation of stress-sensitive signalling pathways. This review highlights these various mechanisms implicated in the cytopathology of mitochondrial disease and dysfunction.
Export Options
About this article
Cite this article as:
Francione Lisa and Fisher R. Paul, Cytopathological Mechanisms in Mitochondrial Disease, Current Chemical Biology 2010; 4(1) . https://dx.doi.org/10.2174/2212796811004010032
DOI https://dx.doi.org/10.2174/2212796811004010032 |
Print ISSN 2212-7968 |
Publisher Name Bentham Science Publisher |
Online ISSN 1872-3136 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Lipid Rafts and Redox Regulation of Cellular Signaling in Cholesterol Induced Atherosclerosis
Current Cardiology Reviews Antimicrobial Agents-Associated with QT Interval Prolongation
Current Drug Safety Mitochondrially Targeted Antioxidants for the Treatment of Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Calcium Homeostasis and Kinetics in Heart Failure
Medicinal Chemistry Autophagy in Chronic Myeloid Leukaemia: Stem Cell Survival and Implication in Therapy
Current Cancer Drug Targets Cardioprotection by Targeting the Pool of Resident and Extracardiac Progenitors
Current Drug Targets Cardiovascular Molecular Imaging: New Methodological Strategies
Current Pharmaceutical Design High-Density Lipoprotein Quantity or Quality for Cardiovascular Prevention?
Current Pharmaceutical Design Microcirculation Dysfunction: A Possible Mechanism Responsible for Reverse Redistribution in Myocardial Perfusion Imaging?
Current Medical Imaging Hypertensive Left Ventricular Hypertrophy Regression: Does It Matter?
Current Hypertension Reviews Molecular Determinants of the Cardiometabolic Phenotype
Endocrine, Metabolic & Immune Disorders - Drug Targets Incidence and Prevalence of Hypothyroidism in Patients Affected by Chronic Heart Failure: Role of Amiodarone
Endocrine, Metabolic & Immune Disorders - Drug Targets Role of Nitrosative Stress and Poly(ADP-ribose) Polymerase Activation in Diabetic Vascular Dysfunction
Current Vascular Pharmacology The LIM Protein fhlA is Essential for Heart Chamber Development in Zebrafish Embryos
Current Molecular Medicine Relaxin, Insulin and Diabetes: An Intriguing Connection
Current Diabetes Reviews Targeting the AMP-Activated Protein Kinase for the Treatment of Type 2 Diabetes
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Exploring the Role of Gene Therapy for Neurological Disorders
Current Gene Therapy Zinc, Metallothioneins and Longevity: Interrelationships with Niacin and Selenium
Current Pharmaceutical Design Cardiotonic Steroids in Adaptation to Dietary Salt Intake
Current Clinical Pharmacology Cellular Cardiomyoplasty – Challenges of a New Era
Current Tissue Engineering (Discontinued)